期刊文献+

考来替兰磷酸盐结合率测定方法研究-离子色谱法

Determination of phosphate binding ratio of colestilan by IC
下载PDF
导出
摘要 考来替兰磷酸盐结合率是临床前药物研究的一项重要内容,该文采用离子色谱法建立考来替兰对磷酸盐结合率的测定方法。采用电导检测器TSKguardcolumn Super IC-Anion HS保护柱及TSKgel Super IC-Anion HS色谱柱,淋洗液为Na_2CO_3(1.1mmol/L)/NaHCO_3(7.5mmol/L),流量为1.0 m L/min。结果表明,方法检出限为0. 02μg/m L,进样量在1.5~30μg/m L范围内线性关系良好(r^2=0.9994),精密度、重复性良好,测定结果的相对标准偏差为0.51%(n=6)。该方法简单方便、稳定可靠,可用于磷结合剂药物对磷酸盐结合率的测定。 The phosphate binding ratio of colestilan is an important part of preclinical drug research.The anions were detected using a suppressed conductivity detector,and TSKguardcolumn Super IC-Anion HS and TSKgel Super IC-Anion HS columns.The eluent used was a Na2 CO3(1.1 mmol/L)/NaHCO3(7.5 mmol/L)mixture and the flow rate was 1.0 m L/min.The detection limit of the method was 0.02μg/m L.The linear range was 1.5-30μg/m L(r2=0.9994).The RSD of determination results was 0.51%(n=6).This method is accurate,reliable and with good reproducibility,and this suggests preferred use of ion chromatography for the determination of phosphate binding ratio of phosphate binders.
作者 李健 梁永庆 乔江波 LI Jian;LIANG Yongqing;QIAO Jiangbo(No.92609 Unit of the PLA,Beijing 100077,China)
机构地区 中国人民解放军
出处 《中国测试》 CAS 北大核心 2018年第A01期85-88,共4页 China Measurement & Test
关键词 离子色谱 考来替兰 磷酸盐 磷结合剂 IC Colestilan phosphate phosphate binders
  • 相关文献

参考文献6

二级参考文献104

  • 1沈磊.抗高磷酸血症新药碳酸镧[J].药学进展,2005,29(6):286-287. 被引量:4
  • 2黄新忠,范亚平,蒋季杰.两种非铝非钙新型磷结合剂的药理与临床[J].国际泌尿系统杂志,2006,26(2):276-279. 被引量:4
  • 3苗华,洪虹,潘明明.聚苯乙烯磺酸镧治疗腺嘌呤性慢性肾衰竭动物模型钙磷代谢异常的实验研究[J].中国血液净化,2007,6(5):272-275. 被引量:5
  • 4李杰,王芃,解砚英,张强,张秀芹,林霞.聚苯乙烯磺酸镧对腺嘌呤致大鼠慢性肾衰高磷血症的治疗作用[J].中国临床药理学与治疗学,2007,12(5):530-534. 被引量:4
  • 5Foley R N,Collins A J,Herzog C A,Ishani A,Kalra P A. Serum phosphorus levels associate with coronary atherosclerosis in young adults[J]. J Am Soc Nephrol, 2009,20 : 397-404.
  • 6Isakova T, Gutierrez O M, Chang Y, Shah A, Tamez H, Smith K,et al. Phosphorus binders and survival on hemodialysis[J]. J Am Soc Nephrol, 2009,20 : 388-396.
  • 7Hutchison A J. Improving phosphate-binder therapy as a way forward[J]. Nephrol Dial Transplant, 2004,19 (Suppl 1) : Ⅰ19-Ⅰ24.
  • 8Koiwa F,Onoda N, Kato H, Tokumoto A, Okada T, Fukagawa M,et al. Prospective randomized muhicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphataemia in hemodialysis patients in Japan[J]. Ther Apheresis Dial, 2005,9: 340-346.
  • 9Nikolov I G, Joki N, Maizel J, Lacour B, Drueke T B, Massy Z A. Pleiotropic effects of the non-calcium phosphate binder sevelamer[J]. Kidney Int Suppl,2006(105) :S16-S23.
  • 10Shantouf R, Budoff M J, Ahmadi N, Tiano J, Flores F, Kalantar- Zadeh K. Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients[J]. Am J Nephrol, 2008,28 : 275-279.

共引文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部